Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database

• Main Authors: Rosanna Ruggiero (Author), Federica Fraenza (Author), Cristina Scavone (Author), Gabriella di Mauro (Author), Raffaele Piscitelli (Author), Annamaria Mascolo (Author), Carmen Ferrajolo (Author), Concetta Rafaniello (Author), Liberata Sportiello (Author), Francesco Rossi (Author), Annalisa Capuano (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundThe introduction of immune checkpoint inhibitors (ICIs) in clinical practice has brought significant benefits for patients. Seven ICIs are available in Europe: nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab, and ipilimumab. Despite their proven clinical efficacy,...